Carly Pearce has made waves in country music with her singing and songwriting, and even earned a Grammy in 2023 for her song ...

On the contrary, if tuberculosis is endemic in the population, empirical anti-tuberculosis therapy is considered for the treatment of pericardial effusions when other causes have been excluded.

In the cited meta-analysis, colchicine was associated with reduced risk of treatment failure (OR: 0.23) and recurrent pericarditis (OR: 0.39), but with a trend toward more adverse effects.

A new study of more than 2,900 patients provides evidence that it's likely best to use as little corticosteroid medicine as ...

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory ...

A new study of more than 2,900 patients provides evidence that it's likely best to use as little corticosteroid medicine as possible when treating people who have lupus pericarditis, a common ...

Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why ...

Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected ...

A summary of the differences is below: There is no medical therapy that works well to treat constrictive pericarditis. Since the stroke volume is relatively fixed, avoiding bradycardia can be helpful.

Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing ...

“So, the biggest cause of what we call recurrent pericarditis is undertreatment of the acute episode,” Klein said. There were no guidelines to treat pericarditis in the U.S. until now and D ...